✦ LIBER ✦

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease

✍ Scribed by Eric A. Vasiliauskas; Lori Y. Kam; Maria T. Abreu-Martin; Philip V. Hassard; Kostas A. Papadakis; Huiying Yang; Jerome B. Zeldis; Stephan R. Targan

Book ID: 118521874
Publisher: Elsevier Science
Year: 1999
Tongue: English
Weight: 175 KB
Volume: 117
Category: Article
ISSN: 0016-5085
DOI: 10.1016/s0016-5085(99)70277-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An open-label phase II study of low-dose

An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer

✍ Drake, M J; Robson, W; Mehta, P; Schofield, I; Neal, D E; Leung, H Y 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 106 KB

Granulocyteaphaeresis in steroid-depende

Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study

✍ E. Domènech; J. Hinojosa; M. Esteve-Comas; F. Gomollón; J. M. Herrera; G. Bastid 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 116 KB

An open-labelled study of granulocyte co

An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease

✍ J. R. Korzenik; B. K. Dieckgraefe 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB

Efficacy and tolerability of rifaximin,

Efficacy and tolerability of rifaximin, a nonabsorbed oral antibiotic, in the treatment of active Crohn’s disease: results of an open-label study

✍ Ira Shafran; Lorin K. Johnson; Lynne Hamm; Robert H. Murdock Jr 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 26 KB